Please assess the completion status of the following clinical trial:

Trial Title: CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for this protocol, subjects must:~1. Be at least 10 kg of body weight.~2. Have a confirmed diagnosis of HAE.~3. Have an acute HAE attack and be able to initiate treatment within 8 hours after onset of symptoms.~Exclusion Criteria:~To be eligible for this protocol, subjects must not:~1. Have any active infectious illness.~2. Have had a prior HAE attack and/or received any C1 INH product within 7 days prior to dosing with study drug.~3. Have received therapy with antifibrinolytics (e.g., tranexamic acid), androgens (e.g., danazol, oxandrolone, stanozolol, or testosterone), ecallantide (Kalbitor®), or icatibant (Firazyr®) within 7 days prior to dosing with study drug.~4. Have a history of allergic reaction to C1 INH products, including CINRYZE (or any of the components of CINRYZE), or other blood products.~5. Have participated in any other investigational drug evaluation within 30 days prior to dosing with study drug, or have previously received treatment with CINRYZE in this study at any time.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- 500 U CINRYZE (10-25 kg body weight) (Type: EXPERIMENTAL): Single IV dose of 500 U CINRYZE
- 1000 U CINRYZE (10-25 kg body weight) (Type: EXPERIMENTAL): Single IV dose of 1000 U CINRYZE
- 1000 U CINRYZE (>25 kg body weight) (Type: EXPERIMENTAL): Single IV dose of 1000 U CINRYZE
- 1500 U CINRYZE (>25 kg body weight) (Type: EXPERIMENTAL): Single IV dose of 1500 U CINRYZE

Based on this trial design, predict the completion outcome and termination type (if applicable).